Pseudovirus Neutralization Assay for BSL-2 Vaccine Immunogenicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing assays for measuring neutralizing antibodies against SARS-CoV-2 viruses require biosafety level 3 (BSL-3) laboratories, which are expensive and difficult to access, necessitating the development of assays that can be performed in biosafety level 2 (BSL-2) laboratories.

Innovation Solution

A pseudovirus-based neutralization assay using pseudoviruses encoding SARS-CoV-2 Spike glycoprotein, Rev, Tat, Gag, and Pol proteins, along with a reporter protein, to evaluate the immune response against SARS-CoV-2 viruses in BSL-2 laboratories.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional assays using SARS-CoV-2 viruses are used to measure neutralizing antibodies, then measurement precision is maintained, but device complexity and operational difficulty increase due to BSL-3 requirements

Engineering Contradiction:

Improveassay accuracyVSAvoidlaboratory safety infrastructure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses pseudoviruses as an intermediary substance that mimics SARS-CoV-2 viral particles but lacks the harmful genetic material. These pseudoviruses express the SARS-CoV-2 spike protein and can be engineered to carry reporter genes, allowing them to serve as safe surrogates for live virus assays while maintaining the ability to measure neutralizing antibodies accurately

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent creates simplified copies of the SARS-CoV-2 virus by using pseudoviral particles that replicate only certain aspects of the real virus (the spike protein expression and cellular entry mechanism) while omitting the dangerous replicative genome. This copying approach preserves assay functionality while eliminating biosafety risks

Inventive Principle:

Principle #26Copying

2Measurement precision

If BSL-3 laboratories are used for SARS-CoV-2 assays, then measurement precision is maintained, but ease of operation deteriorates due to restricted access and stringent safety precautions

Engineering Contradiction:

Improveneutralizing antibody measurementVSAvoidlaboratory access and operational procedures

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

Pseudoviruses serve as an intermediary that enables the assay to be performed in lower biosafety environments. By using these engineered particles that cannot replicate independently, the patent allows laboratories with standard BSL-2 containment to conduct neutralizing antibody assays without requiring the restricted access and complex safety protocols of BSL-3 facilities

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The pseudovirus system uses transient, non-replicating viral particles that are produced in bulk and used immediately for assays. These disposable-like particles eliminate the need for long-term maintenance of high-containment facilities and simplify laboratory operations by removing the need for complex safety infrastructure

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Measurement precision

If BSL-3 laboratories are used for SARS-CoV-2 assays, then measurement precision is maintained, but cost increases due to expensive safety infrastructure and operations

Engineering Contradiction:

Improveneutralizing antibody measurementVSAvoidoperational cost

Core Design Contradiction:

Measurement precisionVSLoss of energy

Solution Approach 1:

By using pseudoviruses as intermediaries, the patent enables the same measurement precision to be achieved in BSL-2 laboratories, which have significantly lower operational costs. The pseudovirus system eliminates the need for expensive BSL-3 infrastructure including specialized ventilation systems, redundant containment barriers, and extensive safety personnel

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The transient nature of pseudoviruses allows for cost-effective assay implementation. These particles can be produced in large quantities using standard cell culture methods and used immediately, eliminating the need for expensive long-term containment infrastructure and reducing operational costs associated with maintaining high-security laboratories

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables the measurement of neutralizing antibodies against SARS-CoV-2 viruses in a cost-effective and accessible BSL-2 laboratory setting, maintaining assay accuracy and reliability.

Implementation Method 1

contacting cells expressing angiotensin converting enzyme 2 with the pseudovirus

Methodology Applied

Scientific EffectViral entry mechanism:

Implementation Method 2

quantifying expression of the reporter protein

Methodology Applied

Scientific EffectReporter protein expression:

Data Source

PatentUS20260028644A1Pseudovirus based neutralization assay for evaluating vaccine immunogenicity

Publication Date: 2026.01.29 NOVAVAX INC

AI summary

Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.